Comparing OPKO Health (OPK) & The Competition

OPKO Health (NASDAQ:OPK) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its peers? We will compare OPKO Health to similar businesses based on the strength of its risk, valuation, institutional ownership, profitability, earnings, dividends and analyst recommendations.

Risk & Volatility

OPKO Health has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, OPKO Health’s peers have a beta of 0.98, indicating that their average stock price is 2% less volatile than the S&P 500.

Profitability

This table compares OPKO Health and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OPKO Health	-12.40%	-5.88%	-3.83%
OPKO Health Competitors	-7.69%	-141.09%	-1.47%

Insider & Institutional Ownership

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 56.8% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares OPKO Health and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OPKO Health	$606.90 million	-$225.68 million	-19.11
OPKO Health Competitors	$21.01 billion	$288.54 million	7.40

OPKO Health’s peers have higher revenue and earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for OPKO Health and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1	1	4	1	2.71
OPKO Health Competitors	1851	7707	13270	815	2.55

OPKO Health currently has a consensus target price of $3.42, suggesting a potential upside of 98.64%. As a group, “Healthcare Providers & Services” companies have a potential upside of 15.98%. Given OPKO Health’s stronger consensus rating and higher possible upside, research analysts plainly believe OPKO Health is more favorable than its peers.

Summary

OPKO Health beats its peers on 8 of the 13 factors compared.

OPKO Health Company Profile

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.